PL2252290T3 - Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym - Google Patents
Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowymInfo
- Publication number
- PL2252290T3 PL2252290T3 PL09710250T PL09710250T PL2252290T3 PL 2252290 T3 PL2252290 T3 PL 2252290T3 PL 09710250 T PL09710250 T PL 09710250T PL 09710250 T PL09710250 T PL 09710250T PL 2252290 T3 PL2252290 T3 PL 2252290T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- osteoarticular diseases
- osteoarticular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/283—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by telescoping of ampoules or carpules with the syringe body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08101682A EP2090307A1 (en) | 2008-02-15 | 2008-02-15 | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
| EP08158285 | 2008-06-13 | ||
| EP09710250.3A EP2252290B1 (en) | 2008-02-15 | 2009-02-13 | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
| PCT/EP2009/051739 WO2009101194A1 (en) | 2008-02-15 | 2009-02-13 | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2252290T3 true PL2252290T3 (pl) | 2018-06-29 |
Family
ID=40550545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09710250T PL2252290T3 (pl) | 2008-02-15 | 2009-02-13 | Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100285134A1 (pl) |
| EP (1) | EP2252290B1 (pl) |
| JP (2) | JP2011512345A (pl) |
| KR (2) | KR101669682B1 (pl) |
| CN (1) | CN101878029B (pl) |
| AU (1) | AU2009214028B2 (pl) |
| BR (1) | BRPI0905369C8 (pl) |
| CA (1) | CA2703866C (pl) |
| DK (1) | DK2252290T3 (pl) |
| ES (1) | ES2658354T3 (pl) |
| HK (1) | HK1149717A1 (pl) |
| IL (1) | IL206080A (pl) |
| NO (1) | NO2252290T3 (pl) |
| PL (1) | PL2252290T3 (pl) |
| PT (1) | PT2252290T (pl) |
| WO (1) | WO2009101194A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2252290T3 (pl) * | 2008-02-15 | 2018-06-29 | Bone Therapeutics S.A. | Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym |
| EP2455097B1 (en) | 2009-07-16 | 2016-02-17 | Sunstar Inc. | Proteoglycan-containing material |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| RU2592850C2 (ru) | 2011-01-19 | 2016-07-27 | Хиросаки Юниверсити | Способ крупномасштабного получения протеогликана |
| WO2013076160A1 (en) | 2011-11-21 | 2013-05-30 | Université Libre de Bruxelles | Sustained release formulations useful in the treatment of diseases |
| WO2013076162A1 (en) * | 2011-11-21 | 2013-05-30 | Université Libre de Bruxelles | Formulations useful in the treatment of osteoarticular diseases |
| SG10201700525PA (en) * | 2012-07-25 | 2017-02-27 | Univ Hirosaki | Composition for preventing or treating osteoarthritis |
| US10646574B2 (en) | 2014-07-21 | 2020-05-12 | Board Of Regents, The University Of Texas System | Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same |
| CN105232453B (zh) * | 2015-10-30 | 2018-11-06 | 上海昊海生物科技股份有限公司 | 关节腔用地塞米松几丁糖纳米注射液及其制备方法 |
| MX2019007923A (es) | 2016-12-31 | 2019-09-10 | Bioxcel Therapeutics Inc | Uso de dexmedetomidina sublingual para el tratamiento de la agitacion. |
| WO2019063320A1 (en) * | 2017-09-27 | 2019-04-04 | Universita' Degli Studi Di Padova | COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES |
| IT201700108102A1 (it) * | 2017-09-27 | 2019-03-27 | Univ Degli Studi Padova | Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie |
| EP3815737B1 (en) | 2018-06-26 | 2023-10-04 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device and method for manufacturing same |
| US10792246B2 (en) | 2018-06-27 | 2020-10-06 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| IT202200004574A1 (it) | 2022-03-10 | 2023-09-10 | Sergio Ammendola | Nanoparticelle di N-acetilglucosammina e loro applicazioni |
| US11622949B1 (en) | 2022-08-04 | 2023-04-11 | Gad M. Gilad | Agmatine compositions for treatment of osteoarthritis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
| US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
| ATE318580T1 (de) * | 1996-12-20 | 2006-03-15 | Alza Corp | Gelzusammensetzungen und verfahren |
| IL129951A0 (en) * | 1997-07-02 | 2000-02-29 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces |
| EP1005874B1 (en) * | 1997-08-22 | 2005-05-18 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, process for producing the same and medical material containing the same |
| WO2000017326A1 (en) | 1998-09-21 | 2000-03-30 | Musc Foundation For Research Development | Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them |
| ES2353061T5 (es) | 2000-04-25 | 2014-04-07 | Osiris Therapeutics, Inc. | Reparación de articulaciones utilizando células madre mesenquimatosas |
| NZ521185A (en) * | 2000-07-14 | 2005-02-25 | Allergan Inc | Compositions containing alpha-2-adrenergic agonist components |
| DE10053053A1 (de) * | 2000-10-19 | 2002-05-16 | Knoell Hans Forschung Ev | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden |
| WO2002089794A1 (en) * | 2001-05-07 | 2002-11-14 | Universite Catholique De Louvain | Method for treating neuropathic pain and pharmaceutical preparation therefor |
| WO2003000190A2 (en) * | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US20070042951A1 (en) * | 2003-10-08 | 2007-02-22 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| WO2005042498A2 (en) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
| WO2006039704A2 (en) | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica, N.V. | Pharmaceutical composition and method for treating a joint capsule arthropathy |
| CA2599718A1 (en) * | 2005-03-04 | 2006-09-08 | Acure Pharma Ab | Methods and pharmaceutical compositions for the treatment of neurological damage |
| RU2008122978A (ru) * | 2005-11-09 | 2009-12-20 | Комбинаторкс, Инкорпорейтед (Us) | Способы, композиции и наборы для лечения медицинских состояний |
| ITPD20060219A1 (it) * | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
| PL2252290T3 (pl) * | 2008-02-15 | 2018-06-29 | Bone Therapeutics S.A. | Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym |
-
2009
- 2009-02-13 PL PL09710250T patent/PL2252290T3/pl unknown
- 2009-02-13 US US12/811,665 patent/US20100285134A1/en not_active Abandoned
- 2009-02-13 PT PT97102503T patent/PT2252290T/pt unknown
- 2009-02-13 BR BRPI0905369A patent/BRPI0905369C8/pt active IP Right Grant
- 2009-02-13 KR KR1020107011867A patent/KR101669682B1/ko active IP Right Grant
- 2009-02-13 JP JP2010546354A patent/JP2011512345A/ja active Pending
- 2009-02-13 AU AU2009214028A patent/AU2009214028B2/en active Active
- 2009-02-13 EP EP09710250.3A patent/EP2252290B1/en active Active
- 2009-02-13 KR KR1020167013799A patent/KR101784642B1/ko active IP Right Grant
- 2009-02-13 CN CN2009801011744A patent/CN101878029B/zh active Active
- 2009-02-13 ES ES09710250.3T patent/ES2658354T3/es active Active
- 2009-02-13 DK DK09710250.3T patent/DK2252290T3/en active
- 2009-02-13 NO NO09710250A patent/NO2252290T3/no unknown
- 2009-02-13 CA CA2703866A patent/CA2703866C/en active Active
- 2009-02-13 WO PCT/EP2009/051739 patent/WO2009101194A1/en active Application Filing
-
2010
- 2010-05-30 IL IL206080A patent/IL206080A/en active IP Right Grant
-
2011
- 2011-04-20 HK HK11104036.5A patent/HK1149717A1/xx unknown
-
2012
- 2012-09-24 US US13/625,601 patent/US9446065B2/en active Active
-
2016
- 2016-08-22 JP JP2016161747A patent/JP6352995B2/ja active Active
- 2016-09-19 US US15/269,216 patent/US9872876B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL206080A0 (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
| IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
| HRP20190059T1 (hr) | Pripravci za liječenje boli i/ili upale | |
| IL210916A (en) | Clonidine and medicinal products containing it for the prevention or treatment of mucosal inflammation | |
| ZA201304638B (en) | Composition for use in the prevention and /or treatment of skin condition and skin diseases. | |
| EP2322221A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER | |
| IL195947A (en) | Manicured cyclic compounds and pharmaceutical preparations containing them for use @ for prevention @ and treatment @ for diabetes | |
| EP2099449A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE | |
| IL207713A0 (en) | Formulation and method for the prevention and treatment of bone metastases or other bone diseases | |
| EP1985302A4 (en) | DRUGS FOR TUMOR THERAPY AND ITS USE | |
| HK1150390A1 (en) | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases | |
| IL206296A (en) | History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases | |
| EP2441453A4 (en) | PHARMACEUTICAL COMPOSITION FOR HUMAN AND ANIMAL MEDICINE OPHTHALMOLOGY | |
| IL210589A (en) | C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB | |
| PL3064579T3 (pl) | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz | |
| EP2217238A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA | |
| EP2206714A4 (en) | AGENT FOR THE PREVENTION AND / OR TREATMENT OF SKIN DISEASES | |
| HK1171677A1 (en) | Composition for the treatment of hemorrhoids and related diseases | |
| EP2231148A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | |
| EP2231146A4 (en) | Pharmaceutical composition for the treatment and prevention of glaucoma | |
| PL2305300T3 (pl) | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
| EP2222295A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF RENAL DISEASES | |
| WO2010149658A3 (en) | Pharmaceutical composition comprising gamma - butyrobetaine and meldonium | |
| EP2441452A4 (en) | PHARMACEUTICAL COMPOSITION AND USE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN MAN AND ANIMAL |